โš  LIVE โ€” European Consumer Safety Watch ๐Ÿ’Š Medicines: 34 in last 7 days ๐ŸŽ Food: 1 in last 7 days ๐Ÿงธ Products: 0 in last 7 days ๐ŸŸข Monitoring: EMA ยท RASFF ยท NVWA ยท FAGG ยท FAVV ยท EFSA ยท Safety Gate โฑ Last fetch: 3 hours ago โš  LIVE โ€” European Consumer Safety Watch ๐Ÿ’Š Medicines: 34 in last 7 days ๐ŸŽ Food: 1 in last 7 days ๐Ÿงธ Products: 0 in last 7 days ๐ŸŸข Monitoring: EMA ยท RASFF ยท NVWA ยท FAGG ยท FAVV ยท EFSA ยท Safety Gate โฑ Last fetch: 3 hours ago
๐Ÿ›ก๏ธ EUSW
๐Ÿ’Š Medicines ๐ŸŽ Food ๐Ÿงธ Products ๐Ÿ”Ž Search
๐Ÿ“Š Data
๐Ÿท Brands ๐ŸŒ Countries โ„น๏ธ About โœ‰ Unsubscribe
๐Ÿ‡ฌ๐Ÿ‡ง
๐Ÿ‡ฌ๐Ÿ‡ง English ๐Ÿ‡ณ๐Ÿ‡ฑ Nederlands ๐Ÿ‡ซ๐Ÿ‡ท Franรงais ๐Ÿ‡ฉ๐Ÿ‡ช Deutsch ๐Ÿ‡ช๐Ÿ‡ธ Espaรฑol ๐Ÿ‡ฎ๐Ÿ‡น Italiano ๐Ÿ‡ต๐Ÿ‡น Portuguรชs ๐Ÿ‡ต๐Ÿ‡ฑ Polski ๐Ÿ‡ธ๐Ÿ‡ช Svenska ๐Ÿ‡ท๐Ÿ‡ด Romรขnฤƒ ๐Ÿ‡จ๐Ÿ‡ฟ ฤŒeลกtina ๐Ÿ‡ซ๐Ÿ‡ฎ Suomi ๐Ÿ‡ฉ๐Ÿ‡ฐ Dansk
๐Ÿ’Š

Lenvima

lenvatinib
Thyroid Neoplasms
โœ… Authorised
โœ…
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.

What it's used for

Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hรผrthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.

โš ๏ธ Patient safety

No

Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima
โš ๏ธ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.